Filing excerpt
In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.
Source: Autobound Signal API · 94 signals tracked for Regeneron · updated
Get Regeneron's live signals in Claude or ChatGPT, or by API
What changed at Regeneron this week? Use Autobound signals for regeneron.com.In August 2026, the FDA approved Pasatru (garetosmab) to reduce new heterotopic ossification lesions and flare-ups in adults with FOP.
Filing excerpt
In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-8kproductLaunchGet every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/ffd4f866-3f82-4312-aaf9-cfc8d0234920 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "ffd4f866-3f82-4312-aaf9-cfc8d0234920",
"signal_type": "sec-8k",
"signal_subtype": "productLaunch",
"detected_at": "2026-11-03T07:04:59.413+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "In August 2026, the FDA approved Pasatru (garetosmab) to reduce new heterotopic ossification lesions and flare-ups in adults with FOP. Commercialization of a newly approved therapy may create demand for patient engagement, specialty distribution, and marketing technology.",
"metrics": {
"timeframe": "last_year"
},
"summary": "FDA Approves Pasatru for Treatment of Fibrodysplasia Ossificans Progressiva",
"excerpts": "In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.",
"relevance": 0.75,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/regn-20261030.htm",
"filing_date": "2026-10-30",
"filing_year": 2026,
"fiscal_year_end": "10/30",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"regions_mentioned": [
"U.S."
]
}
}
curl https://signals.autobound.ai/v1/signals/ffd4f866-3f82-4312-aaf9-cfc8d0234920 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.